Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The investigational new drug XK469 induces G(2)-M cell cycle arrest by p53-dependent and -independent pathways.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Nov 2001

Ding Z, Parchment R E, LoRusso P M, Zhou J Y, Li J, Lawrence T S, Sun Y, Wu G S

Abstract excerpt

PURPOSE: XK469 (2-[4-(7-chloro-2-quinoxalinyloxy) phenoxy]propionic acid), a synthetic quinoxaline phenoxypropionic acid derivative, has broad activity against murine tumors and is entering Phase I clinical development as a topoisomerase IIbeta inhibitor. This study investigated the underlying molecular mechanism of XK469's effects on the cell cycle. EXPERIMENTAL DESIGN: Growth inhibition, cell cycle arrest,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle
Share to Cyclin-Dependent Kinase Inhibitor p21

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclins

Share to Dose-Response Relationship, Drug

Share to G2 Phase

Share to Mitosis

Share to Quinoxalines

Share to Tumor Cells, Cultured

Source

Identifiers

PMID: 11705845

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The investigational new drug XK469 induces G(2)-M cell cycle arrest by p53-dependent and -independent pathways.PMID 11705845Read ↗

A subset of CB002 xanthine analogues bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53Semantic proximity Read ↗

A subset of CB002 xanthine analogs bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53.Semantic proximity Read ↗

Quinacrine-Mediated Autophagy and Apoptosis in Colon Cancer Cells Is Through a p53- and p21-Dependent MechanismSemantic proximity Read ↗

Differential antiproliferative mechanisms of novel derivative of benzimidazo[1,2- α ]quinoline in colon cancer cells depending on their p53 statusSemantic proximity Read ↗

The Mutant p53-Conformation Modifying Drug, CP-31398, Can Induce ApoptosisSemantic proximity Read ↗

APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma.Semantic proximity Read ↗

Buxus alkaloid compound destabilizes mutant p53 through inhibition of the HSF1 chaperone axis.Semantic proximity Read ↗

Distinct novel quinazolinone exhibits selective inhibition in MGC-803 cancer cells by dictating mutant p53 function.Semantic proximity Read ↗

Design, Synthesis and In Vitro Activity of Anticancer Styrylquinolines. The p53 Independent Mechanism of Action.Semantic proximity Read ↗

Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancerSemantic proximity Read ↗

Identification and characterization of drug resistance mechanisms in cancer cells against Aurora kinase inhibitors CYC116 and ZM447439Semantic proximity Read ↗

Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.